Navigation Links
Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
Date:2/26/2009

RALEIGH, N.C., Feb. 26 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched XYLAREX - a first-in-class nonantibiotic for the dietary management of recurrent acute otitis media (middle ear infections). XYLAREX is a novel oral solution intended to be administered daily to reduce the number of ear infections children experience. The primary ingredient in XYLAREX has also been shown to reduce the amount of antibiotics prescribed to children affected by middle ear infections. XYLAREX can be administered to children as young as six months of age.

Acute Otitis Media (AOM) is the most common bacterial illness of childhood and the primary reason antibiotics are prescribed for children in the U.S. Recurrent AOM affects millions of U.S. children each year, and children suffering from repeated, painful ear infections are frequently exposed to numerous courses of antibiotics at a young age. With repeated antibiotic exposure there is an increased risk of developing bacterial resistance, which the Centers for Disease Control and Prevention (CDC) call one of the world's most pressing health concerns.

"Until now there have been limited options for managing children with recurrent acute otitis media. Pediatricians and otolaryngologists alike see many children with recurrent ear infections who have been subjected to countless antibiotic courses and - in severe cases - may require ear tube placement to alleviate symptoms. Parents and clinicians are looking for new options for these children. A novel, non-drug product like XYLAREX is an important new option for managing children with recurrent AOM in order to reduce their infections and decrease their need for antibiotics," says Mark Mehle, M.D., a practicing ear, nose, and throat physician in Cleveland, Ohio.

According to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals, "XYLAREX is a very important product as it represents a first-in-class non-drug therapy with the potential to positively impact the lives of millions of children suffering from recurrent ear infections. Arbor is firmly dedicated to health of children, and XYLAREX will be a significant addition for the management of common ear infections."

XYLAREX is available by prescription and can be obtained from retail pharmacies across the U.S. XYLAREX is being introduced to U.S. pediatricians by Arbor Pharmaceuticals' specialty sales force. XYLAREX is Arbor Pharmaceuticals' third product introduction since the company initiated commercial operations less than two years ago.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. The company intends to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for significant pediatric conditions. The company currently focuses on nonantibiotic products for the treatment of various ear infections including ZINOTIC(R) for acute otitis externa and NEOTIC(R) for acute otitis media. XYLAREX is the latest addition to the Arbor Pharmaceuticals product portfolio and is indicated for the dietary management of recurrent acute otitis media.

To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.


'/>"/>
SOURCE Arbor Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Cold Spring Harbor scientists devise novel, low-cost method of sifting genomes high-value regions
3. Cold Spring Harbor Protocols features innovative methods for embryology research
4. Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils
5. Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity
6. Harborview Medical Center Implements Latest Release of the DocuSys Solution to Improve Anesthesia Medication Safety and Documentation
7. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
8. Does 1q31.1-32.1 harbor a tumor suppressor gene related to Chinese SCC patients?
9. Cold Spring Harbor scientists reveal a proteins role in enabling AIDS virus to reproduce
10. Cold Spring Harbor science teams identify 13 new tumor-suppressor genes in liver cancer
11. Announcing a Monumental Sharing of Laser Innovation: The American Society for Laser Medicine and Surgery (ASLMS) Holds 29th Annual Conference in National Harbor, Md., April 1 - 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology: